An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Targeting non-invasive treatment for cardiac amyloidosis
Targeting non-invasive solution to treating cardiac amyloidosis
Studying heart disease… in the 3rd trimester
What do dramatic blood flow changes inside expecting mothers mean for women with pre-existing heart conditions – and the unborn babies inside them?